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a b s t r a c t
Proton magnetic resonance spectroscopic imaging (1H MRSI) enables non-invasive assessment of certain
metabolites in the prostate gland. Several studies have demonstrated that this metabolic information, in
combination with anatomical information from T2-weighted MR imaging signiﬁcantly improves prostate
cancer detection, localization and disease characterization. The technology of 1H MRSI is continuously
evolving with improvements of hardware and acquisition methods. Recently, 31P and 13C MRSI of the
prostate have regained new interest after a dormant period of decades.
This review focuses on recent technical progress of in vivo 1H MRSI of the prostate, in particular those
that enhance clinical applicability at 3T with respect to commonly used techniques to examine the
prostate. These developments consist of higher magnetic ﬁeld strengths, and better MR coils and
acquisition techniques. Besides the improvements for 1H MRSI, the developments and opportunities for
31P and 13C MRSI for the prostate are reviewed. Finally, we brieﬂy review 13C MRS of the prostate, in
particular the new possibilities with hyperpolarized substrates.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
MR imaging is increasingly being used in the clinical manage-
ment of prostate cancer such as for the detection and localization of
cancer tissue, and to assess the stage and aggressiveness of the
disease. This is currently performed by multi-parametric MR im-
aging (mpMRI) of the prostate, consisting of T2-weighted imaging
to visualize prostate anatomy, complemented with one or more
functional MR techniques including diffusion weighted imaging
(DWI) and dynamic contrast enhanced imaging (DCE-MRI) [1]. For
the interpretation of mpMRI in cancer detection a reporting system
called PIRADS has been developed, which assesses the likelihood of
clinically signiﬁcant disease [2,3]. As MR spectroscopic imaging
(MRSI) has been demonstrated to be valuable in the diagnosis,
localization and characterization of the disease [1,4e9] it was
included in the original PI-RADS, but not in themost recent version,
PI-RADS 2.0, due to the low practicality of current 1HMRSImethods
in routine clinical use. In particular non-standardized and some-
times rather long examinations, the need for in-house expertise,
lack of standardized automated processing and adequate data
display limit the application of prostate MRSI mainly to clinical
research.
There are many recent developments that might lead to a more
prominent role for MRSI in prostate cancer management such as
improved radiofrequency (RF) coils, faster and more robust acqui-
sition schemes with a higher sensitivity, and more dedicated
automatic processing software. In addition, important advances on
ultra-high ﬁeld 7T MR systems enable to achieve higher spatial
resolutions in 1H MRSI and to perform 3D 31P MRSI of the entire
prostate. Finally, the introduction of in vivo 13C MR spectroscopic
imaging of the human prostate using hyperpolarized compounds
opens new possibilities for the characterization of prostate cancer.
Acknowledging the previously published review articles on
clinical 1H MRSI of prostate cancer [4e8], here we will highlight (i)
the recent technical developments in 1H MRSI, (ii) recent results on
1H and 31P MRSI at 7T MR systems, and (iii) 13C MRS applications in
prostate cancer.
2. 1H MRSI of the prostate
Since the ﬁrst acquired 1H MR spectra of the prostate in 1990
[10], substantial progress has been made in the methodology with
higher ﬁeld strengths and improved coils and acquisition tech-
niques. These improvements make it possible to acquireMR spectra
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of voxels with sizes in the order of 0.5 cm3 with sufﬁcient SNR and
spectral resolution to detect metabolites throughout the entire
prostate in a clinically feasible measurement time.
3. MR hardware
3.1. Field strength
The ﬁrst in vivo 1H spectra of the prostate were obtained at a
ﬁeld strength of 2T [10]. Nowadays instruments with ﬁeld strengths
of 1.5T and 3T are commonly used, along with some initial exper-
iments at 7T. Higher magnetic ﬁeld strengths offer increased
spectral resolution and higher signal-to-noise ratio (SNR), but are
challenged by the absorption of RF by the tissue, and by increased
susceptibility variations causing faster signal attenuation of the free
induction decay, adversely affecting SNR and spectral line widths. A
comparison for MRSI between 1.5T and 3T showed an SNR
improvement by a factor of 2 [11]. This increase in SNR enables a
higher spatial and/or temporal resolution. At higher spatial reso-
lution SNR is relatively enhanced due to reduced intra-voxel de-
phasing [11]. No comparison in SNR or spatial/temporal resolution
between 3T and 7T in prostate is available yet, but such studies of
the brain suggest a more accurate assessment of metabolites levels
at higher ﬁeld strength [12,13].
The increased frequency dispersion at higher ﬁelds improves
the separation between metabolite resonances, but also requires
pulses with more RF power deposition, reaching or exceeding the
maximum speciﬁc absorption rate (SAR) limit. To stay within SAR-
limits, an increase in repetition time (TR) might be necessary,
which results in longer acquisition times. Clever acquisition
schemes to deal with these challenges will be discussed below.
3.2. RF coils
MR(S)I of the prostate is generally performedwith an integrated
body coil for excitation together with external phased array coils
and/or endorectal coil for signal reception. The use of an endorectal
coil is recommended for MRSI at 1.5T, but optional at 3T, due to its
proximity to the prostate. The spectral quality of MRSI data at 1.5T
with endorectal coil is comparable to that at 3T without endorectal
coil except for the voxels close to the endorectal coil, which have a
higher SNR [14]. At 3T a mild but signiﬁcant improvement in
prostate cancer localization using 1H MSRI was observed when an
endorectal coil was used compared to no endorectal coil [15].
However, no difference in cancer localization performance was
observed at 1.5T between both coil conﬁgurations [16].
As 7T MR-systems lack an integrated body coil, local coils are
required that can both transmit and receive RF-signals. The ﬁrst 1H
MR spectra of the prostate at 7T were obtained with a transmit/
receive endorectal loop-coil [17,18]. A loop coil provides high
sensitivity for adjacent tissue of interest, but suffers from transmit
ﬁeld (B1þ) and receive ﬁeld (B1) inhomogeneity. To compensate for
RF ﬁeld inhomogeneity, adiabatic RF pulses have been applied [16],
providing a uniform RF ﬁeld over the region of interest (see pulse
sequence section). Others have developed an external transmit/
receive 8-channel phased array coil for prostate imaging at 7T [19].
As the 1H wavelength is short at 7T, destructive interferences can
occur. To generate an homogenous and constructive B1þ-ﬁeld in the
prostate with this setup, B1þ-shimming is required [19]. During B1þ-
shimming, the phase of each transmit-channel is optimized in or-
der to have a constructive B1þ in the prostate. Next to receiving with
an external array coil for 1H MRSI, these 8-channel coils can also be
combined with a receive-only endorectal coil [20,21].
The use of an endorectal coil has some issues: the positioning is
time consuming, demands a level of expertise, and can be
uncomfortable for patients. Most often, an endorectal coil with an
inﬂatable balloon is used, which brings the coil close to the pros-
tate. With a dual-channel inﬂatable coil the SNR and image quality
is increased compared to common single loop endorectal coil [22].
Note however, an inﬂatable balloon changes the shape and size of
the prostate signiﬁcantly, which can cause difﬁculties if the images
are used for subsequent treatment [23]. Recently, a rigid reusable
dual-channel endorectal coil became available that provided an
increased SNR and image quality up to 3 cm from the coil compared
to the single loop inﬂatable coil [24].
4. Acquisition
4.1. Pulse sequence
Initially, merely the ﬁeld of view of the endorectal coil was used
to localize prostate spectra [10]. Subsequently, in vivo single voxel
MRS of the prostate was performed [25,26]. Due to the multi-focal
nature of prostate cancer, single voxel MRS is inadequate for
prostate applications and MR spectroscopic imaging was intro-
duced [27e31]. Using phase-encoding in three directions and
weighted elliptical k-space sampling, spectra of the entire prostate
were obtained in 8e15minwith nominal voxel sizes down to 0.4 cc
at a ﬁeld strength of 1.5T [31].
Volume localization in the prostate was ﬁrst performed using
point-resolved spectroscopy (PRESS) [25] and stimulated echo
acquisition mode (STEAM) [26], of which the former is commonly
used in the clinic to acquire prostate spectra (Fig. 1A). The inter-
pulse timing and magnetic ﬁeld strength affect the spectral
appearance of some compounds detectable in prostate spectra [7],
which will be discussed in more detail in the section on
metabolites.
In 2009, the use of adiabatic pulses for localization by adiabatic
selective refocusing (LASER) was introduced for prostate MRSI
[17,32]. They have better slice proﬁles, reducing outer volume
signal contamination, are less sensitive to B1þ inhomogeneities, and
have large bandwidths, thus diminishing chemical shift displace-
ment artifacts. However, the pulses are RF power-demanding and
need to be played out in pairs to achieve a homogeneous phase
distribution over the selected slice. To lower RF power deposition,
GOIA (gradient-modulated offset independent adiabaticity) pulses
[33] are used that require less RF to reach adiabaticity [34], and
slice-selective excitation is performed by a single conventional 90
excitation pulse: the semi-LASER (sLASER) sequence (Fig. 1B)
[35,36]. At 3T, the measurement time for 3D MRSI using sLASER
with GOIA pulses can be reduced to about 5 min without an
endorectal coil with a nominal voxel resolution of 7  7  7 mm
[37].
The transmit/receive endorectal coil used for 3D 1H MRSI at 7T
has a very inhomogeneous B1. This can be addressed by LASER se-
quences which are insensitive to B1þ inhomogeneities [17]. As the
excitation pulse in the sLASER sequence is non-adiabatic, sequences
were introduced using either a composite adiabatic slice-selective
excitation (cLASER) or a non-slice-selective adiabatic excitation
(nsLASER), allowing for shorter TEs, whilst maintaining the adia-
batic spin excitation [38,39]. However, long repetition times were
required due to high RF power deposition and SAR limitations,
leading to long measurement times. These SAR-issues were
addressed in a feasibility study at 7T using external phased array
coils and a double spin-echo with asymmetric slice selective exci-
tation pulses and a pair of spectral-spatial pulses. The spectral-
spatial pulses excite and refocus only the metabolites of interest
and eliminate the need for additional water or lipid suppression
pulses [20]. The potential of 3D MRSI at 7T in prostate cancer re-
quires further research.
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As prostate MRS measurements may suffer from movement
artifacts, motion reduction is essential. This can be tackled by
several approaches such as limiting bowel movement using anti-
peristaltic drugs and the application of a navigator [40]. MRSI
data can be measured faster by simultaneous sampling in spatial
and spectral dimensions, e.g. by traversing k-space in several short
spiral trajectories within one read-out period [41,42]. Besides the
time-gain of this approach, the spiral readouts start at the center of
the k-space, which enables correcting for motion induced phase
variations [42]. Spiral k-space acquisitions are an attractive ﬂexible
alternative to a Cartesian sampling grid for prostate MRSI [43].
4.2. Suppression of contaminating lipid and other signals
The prostate is surrounded by lipid tissue, which may cause
large resonances in the ppmerange close to those of citrate, which
is one of the important prostate metabolites. Great care should be
taken to prevent lipid signal contamination in prostate spectra. To
achieve this several techniques have been used: outer volume
saturation (OVS), additional pulses for lipid and water suppression,
frequency selective excitation or refocusing, and k-space
apodization.
OVS slabs can be placed around the prostate (Fig. 2) to pre-
saturate signals from peri-prostatic lipids. The signals of the
excited spins are crushed with dephasing gradients. Conventional
OVS bands are optimized to compensate for poor edge proﬁles, B1
ﬁeld inhomogeneity and chemical shift errors [44]. Very selective
saturation (VSS) pulses have a reduced B1 and T1 dependency [44].
The saturation slabs are usually positioned manually; however, in
conformal voxel MRS, the assignment of spatial saturation planes is
optimized by automatic placement, orientation, timing and ﬂip
angle setting of VSS pulses around the excitation volume based on
the shape of the prostate [45,46]. To facilitate clinical use of prostate
MRSI, automation of certain steps such as prostate volume seg-
mentation, ﬁeld of view and 3D volume selection and OVS place-
ment are warranted.
Additionally, dual-frequency selective MEGA pulses have been
incorporated in prostate MRSI to suppress lipid and water reso-
nances (Fig. 1). The RF pulses selectively refocus water and lipid
signals and are surrounded by crusher gradients to dephase the
water and lipid spins while those of the metabolites of interest
remain unaffected [47]. MEGA pulses are used in 3D 1H MRSI se-
quences such as PRESS [31], GOIA-sLASER [36], cLASER, nsLASER
[38].
Unnecessary excitation of peri-prostatic lipids and water can
also be prevented by spectral-spatial selective RF pulses [11]. Dual
band spectral-spatial RF pulses for prostate MRSI were speciﬁcally
developed to fully excite the prostate metabolites and partially the
water resonance [48]. The applicability of spectral-spatial pulses for
prostate MRSI has been successfully demonstrated at 1.5T, 3T and
7T [11,20,48].
Next to robust suppression of lipid signals, signal contamination
from neighboring voxels including lipids should be minimized. In
conventional MRSI acquisitions, a standard Cartesian grid is
sampled in k-space covering two or three spatial phase encoded
dimensions. The limited number of k-space steps in MRSI results in
a poor spatial response function (SRF) leading to inter-voxel signal
contamination. Application of a suitable apodization ﬁlter in k-
space can smooth the SRF to minimize signal contamination at the
cost of a larger voxel size [49]. Combining this apodization with a
weighted elliptical k-space sampling scheme results in a consid-
erably shorter acquisition time with sustained sensitivity [31].
5. Prostate metabolites in 1H MRSI
Proton MR spectra of prostate tissue commonly contain signals
from citrate (Cit), choline-containing compounds (tCho), creatine
(Cr) and polyamines (PA) (Fig. 2). As metabolite signal intensities
are used as biomarkers for prostate cancer or prostate abnormal-
ities like benign prostatic hyperplasia (BPH), understanding the
origin of these signals and the underlying mechanisms leading to
metabolic changes is essential.
5.1. Citrate
In the normal human prostate epithelial cells secrete Cit in the
luminal space, where it accumulates at high concentrations
[50,51](Fig. 3). In numerous studies it has been demonstrated that
tissue levels of Cit are reduced in prostate cancer and thus may
serve as an in vivo marker to discriminate cancer from normal
prostate tissue [25,26,29,52]. The likely processes that contribute to
this decrease are the lower secretion of Cit in the lumen and a
reduced luminal space in prostate cancer (Fig. 3). As expected from
its luminal accumulation, Cit levels are higher in glandular than in
stromal tissue [53,54]. For this reason these levels vary between
different zones of the human prostate [55e57] and may be
increased in mixed tissue BPH compared to normal prostate tissue
[53,54].
The protons of Cit resonate around 2.6 ppm, but the precise
chemical shift and the scalar coupling of these protons depend on
pH [58] and cation concentration [59]. Twomagnetically equivalent
methylene groups are present in Cit and the protons in these -CH2-
groups are strongly coupled. Therefore, the spectral shape of Cit
depends on inter-pulse timing including TE, pulse shape, and ﬁeld
strength. Several optimization studies have been conducted to
optimize Cit detection at 1.5Tand 3T [36,60e62], inwhich the inter-
Fig. 1. Schematic diagrams of RF pulses in 3D prostate MRSI with MEGAwater and lipid suppression pulses. A) PRESS: Localization is performed with a 90 excitation pulse and two
conventional 180 refocusing pulses. The echo time (TE) is deﬁned as two times (t2). Before excitation, outer volume saturation (OVS) pulses saturate peri-prostatic lipid signals. B)
sLASER: After excitation with a conventional slice selective excitation pulse, the signal is refocused with two pairs of slice-selective low-power adiabatic refocusing pulses (WURST
(16,4) modulated GOIA pulses).
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pulse timing was optimized to invoke absorptive Cit signals in the
spectrum. For double spin-echo techniques, two variables (t1 and
t2) and for the sLASER sequence four delays (t1 to t4) can be
changed at a constant TE to optimize the shape (Fig. 1A and B). TEs
Fig. 2. MR(S)I data of a patient with a Gleason score (3 þ 4) prostate cancer in the left transition zone. The patient was measured with both the PRESS and GOIA-sLASER sequence at
3 T. On the T2w images with the spectroscopy grid (C) and (D) the location of the normal voxel (blue) and tumor voxel (red) is indicated. Representative spectra from normal
appearing tissue acquired with PRESS (A) and GOIA-sLaser (E), and tumor tissue acquired with PRESS (B) and GOIA-sLaser (F) illustrate the differences in metabolite signal in-
tensities between healthy and tumor tissue. The PRESS data was measured at TR/TE ¼ 1020/145 ms and the GOIA-sLASER data was measured at TR/TE ¼ 1020/88 ms. Indicated are
the main prostate metabolites: citrate (Cit), choline (Cho), spermine (Spm) and creatine (Cr). Healthy spectra A and E have the same scaling, and tumor spectra B and F have the
same scaling, showing the increase in SNR of the GOIA-sLASER sequence compared to PRESS. Note that because of their different distances to the endorectal coil, scaling between
tumor and healthy voxel was different.
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between 120 and 130 ms at 1.5T and between 75 and 145 ms at 3T
are used by the major MR vendors [7]. Published T1 and T2 relax-
ation times for Cit at 1.5T and 3T are provided in Table 1, taking into
account the changes in citrate shape with TE. As Cit has a relatively
short T1, a short TR can be used, whichminimizes acquisition times.
5.2. Total choline (tCho): free choline, glycerophosphocholine and
phosphocholine
Choline-containing compounds are involved in the biosynthesis
and degradation of phospholipids that are essential elements of
Fig. 3. Citrate production in the prostate [50,51]. A) The hematoxylin and eosin (H&E) stained histopathological slice of the normal prostate on the right-, shows acini, surrounded
by epithelial cells and ducts. Citrate is present at high concentrations in the luminal space of these glandular structures [63,64]. Cho and Cr are mostly present in stromal tissue
including smooth muscles. On the left, is a schematic overview of the metabolic pathways related to citrate productions in a normal epithelial cell. Citrate is synthesized in the
mitochondria and limited in its further metabolization to isocitrate due to blockage of the pathway by the inhibition of aconitase (ACON) by zinc (Zn2þ). The epithelial cells then
secrete Cit into the luminal space where it accumulates to high concentration (blue arrow). B) On the right, a stained H&E slice of tumor tissue illustrates a reduced luminal space
due to invasion of cancer cells. The altered citrate metabolism indicated on the left is caused by less inhibition of aconitase and Cit is mostly oxidized in the Krebs cycle rather than
secreted out of the cell. *OAA: oxaloaceticacid, ACON: aconitase, AcCoA: Acetyl coenzyme A, a-KG: a-ketoglutarate.
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cellular membranes. An increase in the tCho signal is observed in
in vivo 1HMRSI of prostate cancer tissue [27,29], which is associated
with neoplastic changes in cell membrane synthesis and degrada-
tion [65,66].
The choline-containing metabolites that contribute to the main
peak at 3.2 ppm in in vivo proton MR spectra are free choline,
glycerophosphocholine and phosphocholine. Ex vivo HRMAS
studies indicate that all choline compounds contribute to the tCho
increase in prostate cancer tissue [53,67,68]. In vivo differentiation
between the tCho compounds by 1H MRS is difﬁcult because of the
small chemical shift difference in comparison to the broad spectral
linewidth, hence the referral to the composite signal at 3.2 ppm as
total Cho.
The tCho signal at 3.2 ppm arises from 9magnetically equivalent
protons in 3 methyl groups. The other observable protons in the
tChometabolites resonate at 3.54 and 4.05 but (partly) overlapwith
resonances from taurine and ethanolamine containing metabolites
[67].
5.3. Polyamines/spermine
About 50e90% of the polyamines (PA) in the prostate is sper-
mine (Spm). Like Cit, it is secreted in the luminal space by ductal
cells [69e71] and known to decrease in prostate cancer [68,71,72].
Absolute tissue levels of spermine were quantiﬁed by in vivo single
voxel MRS at short TE [72,73].
Spm is a coupled spin system containing two amine groups, two
amide groups and ten methylene groups (CH2). These methylene
protons resonate in ﬁve sets of four magnetically equivalent pro-
tons at 1.81 ppm, 2.11 ppm, 3.13 ppm, 3.12 ppm, and 3.18 ppm [74].
Similar to Cit, the Spm spectral shape and dispersive components
are affected by inter-pulse timing and ﬁeld strength. Interestingly,
by partial refocusing of coupled spins due to the frequency-
selective refocusing scheme, the Spm signal in in vivo 7T prostate
spectra appeared unexpectedly large (Fig. 4) [17,20,75]. In
retrospect, perhaps in some earlier studies at 1.5 and 3T the signal
intensity of Spm has been underestimated to some extent because
of overlapping Cr and tCho signals.
5.4. Creatine and phosphocreatine (tCr)
In 1HMR spectra of the prostate themethyl protons of tCr have a
resonance at 3.03 ppm. Its methylene peak at 3.91 ppm is usually
not seen in vivo. Stromal tissue in the prostate mainly consists of
ﬁbroblasts and smooth muscle cells [76], of which the latter
probably contribute most to the Cr resonances in prostate MRSI.
The total creatine (tCr) signal consists of resonances from free
creatine and phosphocreatine (PCr), compounds that play a key role
in storage and transfer of energy [77]. PCr supports adenosine
triphosphate (ATP) levels in tissue by supplying phosphate to
adenosine diphosphate (ADP) to form ATP [78]. In 1H HR-MAS
spectroscopy studies, no signiﬁcant difference in tCr levels be-
tween normal prostate and cancer tissue was observed [53,68], in
agreement with similar values for the stromal component in
normal and cancer tissue [8,79] although a small decrease of this
component is observed with higher Gleason grades [80]. Only in
very high-grade tumors or after hormonal deprivation therapy a
decrease of the tCr signal is observed [81].
5.5. Other metabolites
Besides the four major metabolites visible in in vivo 1H MR
spectra of the prostate, other metabolites with shorter T2 or J-
coupled protons may become visible at echo times below about
100 ms. Already at TE ¼ 88 ms signals for myoinositol and taurine
are recognizable [82]. At still shorter TE, also signals for,scyllo-
inositol and glutamine/glutamate become detectable in prostate
spectra [45,73]. The value of these metabolites as biomarker for
prostate cancer requires further investigation. Metabolite proﬁling
in prostate tissue suggested myo-inositol as biomarker for
Table 1
T1 and T2 relaxation times and in vivo measured concentration of prostate metabolites (Mean ± SD). *PZ ¼ peripheral zone, TZ ¼ transition zone, CG ¼ central gland.
Metabolite Reference 1.5T in vivo MRS
T1 (sec) T2 (sec) concentration (mM)
Choline Heerschap et al., 1997 [28] 0.84 ± 0.09 0.23 ± 0.06 3.1
Citrate 0.34 ± 0.04
Creatine 0.86 ± 0.1 0.21 ± 0.1 4.4 ± 0.8
Citrate Heerschap et al.[116] 0.18 ± 0.1
Citrate Lowry et al., 1996 [56] 0.84 ± 0.08 0.17 ± 0.02 (PZ)
0.12 ± 0.03 (TZ)
3T
Choline Scheenen et al., 2005 [61] 1.1 ± 0.4 0.22 ± 0.09
Citrate 0.47 ± 0.14 0.17 ± 0.05
Choline Weis et al., 2013 [117] 0.987 ± 0.071 0.239 ± 0.024 2.6 ± 0.3
Citrate 0.476 ± 0.07 0.11 ± 0.018 26.9 ± 5.5
Creatine 1.128 ± 0.149 0.188 ± 0.020 5.8 ± 1.3
Basharat et al., 2014 [73] Normal CG Normal PZ
Choline 0.062 ± 0.017 5 ± 4 7 ± 3
Spermine 0.053 ± 0.016 7 ± 4 10 ± 4
myo-inositol 0.090 ± 0.048 15 ± 12 10 ± 8
Creatine 8 ± 7 9 ± 5
Citrate 32 ± 17 64 ± 22
Basharat et al., 2015 [72] Normal tissue Tumor
Choline 0.073 ± 0.027 4 ± 3 4 ± 2
Spermine 0.096 ± 0.056 9 ± 3 6 ± 3
myo-inositol 18 ± 5 14 ± 7
Creatine 9 ± 7 10 ± 5
Citrate 50 ± 34 19 ± 11
Citrate Liney et al., 1997 [55] 40
Spermine Kavanagh et al., 1985 [118] 12
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localization of malignancy in the prostate [83]. Lactate is another
metabolite of interest for cancer characterization and has been
found in high concentrations in brain tumors [84]. However, no
lactate signal was detectable in in vivo 1H MRSI of the prostate and
it was concluded that its concentration is low (<1.5 mM) even in
high-grade prostate cancer [85].
6. Processing and interpretation of 1H MRSI data
Intensity decreases of Cit and PA and increase in tCho signals can
be used as a biomarker for malignancies in the prostate. For pros-
tate cancer localization and characterization, generally a metabolite
ratio, e.g. (Cho þ PA þ Cr)/Cit, is used instead of individual
metabolite maps.With an endorectal coil, the individual metabolite
maps suffer from B1 ﬁeld inhomogeneity, because signal intensity
of the coil drops towards the ventral parts of the prostate. Recon-
struction of individual maps of tCho, PA and tCr maybe hampered
by overlap of their resonances.
Calculations of absolute metabolite levels require an additional
measurement (and thus more time) to acquire the water signal for
internal referencing. Furthermore, in prostate MRSI usually long
TEs are used, which should be accounted for in quantiﬁcation. For
these reasons absolute quantiﬁcation of prostate metabolites is not
frequently applied [28,56]. The use of a metabolite ratio as
biomarker for prostate cancer solvesmany of these issues. To obtain
ratios, the signals should be ﬁtted or integrated. The many aspects
to consider in ﬁtting procedures are beyond the scope of this paper.
For detailed information on post-processing of prostate spectra and
interpretation of metabolite ratios, we refer to review papers that
address these issues [4,8].
The (tCho þ PA þ tCr)/Cit ratio increases in cancer compared to
normal prostate tissue due to a decrease in Cit (and Spm) together
with an increase in tCho (Fig. 3). The decrease of Cit and Spm levels
seen in 1HMR spectra of prostate cancer lesions may be caused by a
remodeling of their metabolism by morphological changes in the
gland leading to a decrease in luminal space in cancer tissue [86]. A
substantial loss (>50%, depending on Gleason pattern [79,80,87] of
luminal space by dedifferentiating epithelial cancer cells results in
less space for Cit and Spm to accumulate. Indeed, a signiﬁcant
correlation between the percentage area of luminal space and the
(Cit þ Spm þ tCr)/tCho ratio has been observed [87].
The fact that the (tCho þ PA þ tCr)/Cit ratio is higher in cancer
tissue compared to normal prostate tissue enables us to use the
ratio for prostate cancer detection and localization [52,88,89]. The
applicability of the (tCho þ tCr)/Cit ratio to differentiate between
tumor and normal prostate tissue has been demonstrated in amulti
center study [90]. Furthermore, the ratio correlates with the Glea-
son score, a histological score for the aggressiveness of the tumor
[91,92]. Although the current role of 1H MRSI in clinical mpMRI is
limited there is ample evidence it has added value. The perfor-
mance of the metabolite ratio for a noninvasive in vivo aggres-
siveness assessment is comparable to the performance of the
apparent diffusion coefﬁcient obtained from DWI [91]. 1H MRSI
outperformed DWI when assessing aggressiveness in transition
zone (TZ) tumors [91]. When combining multiple modalities, 1H
MRSI in combination with the wash-out, a parameter of DCE-MRI,
gave the best performance for discrimination between low and
high-grade tumors in the TZ [93].
7. 31P MRSI of the prostate
The ﬁrst 31P MR spectra of the prostate were acquired at 1.5 and
2T in the early nineties using a 31P transmit/receive endorectal coil
[94,95]. These spectra were unlocalized and the obtainedmetabolic
information originated from the complete ﬁeld of view of the coil.
To study different parts of the prostate, the coil had to be reposi-
tioned between acquisitions [96]. Furthermore, the anatomical
images were obtained in a separate session using a 1H coil. After
these initial studies, interest in in vivo 31P MRS of the prostate
dropped and only received new attention twenty years later with
the introduction of ultra high ﬁeld 7T MR-systems. The increase in
SNR at this higher ﬁeld strength enables 31P 3D MRSI studies of the
entire prostate in one session. Furthermore, the increase in spectral
resolution makes it possible to better discriminate between
metabolite signals. In this section we will discuss the information
content and technical challenges of 3D 31P-MRSI at 7T.
8. Hardware
As ultra-high ﬁeld MR systems lack an integrated body coil, local
coils are required that can both transmit and receive RF-signals. For
the acquisition of 3D 31P MRSI, two frequencies are of interest: the
Fig. 4. : 1H MRSI of a patient with prostate cancer at 7 T. A) Spectral map of the full ﬁeld of view overlaid on top of a transversal T2w image. B) Spectrum of a non-cancer tissue
indicated by the yellow square on the spectral map. The prostate metabolites Cit, consisting of a double doublet, total choline (tCho) and a large spermine (Spm) signal that obscures
the creatine resonance are indicated.
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1H frequency for anatomical reference images and manipulation of
1H-31P interactions, and the 31P frequency at which the spectra are
acquired. Two different approaches have been presented to achieve
this for 31P MRSI of the prostate at 7 T. For the ﬁrst approach, an 8-
channel 1H phased-array body coil was placed around the pelvic
area of the subject and this was combined with a 31P transmit/
receive endorectal [97]. Another approach is the use of an endor-
ectal loop-coil tuned to both the 1H- and the 31P-frequency [98]. A
challenge when using an endorectal coil for signal transmission is
that the B1þ drops at larger distances from the coil, which will be
discussed inmore detail in the acquisition section. The futuremight
bring new set-ups involving external 31P coils or other combina-
tions of transmit and receive coils.
9. Acquisition
The use of an endorectal loop-coil, essential to address the lower
sensitivity of the 31P nucleus has both advantages and disadvan-
tages for 31P MRSI. Since the B1 drops further from the coil, the
transmit and receive ﬁelds are inhomogeneous. To ensure that the
ﬂip angle is the same over the entire prostate, adiabatic pulses can
be used [97,99]. To stay within SAR-limits, only a limited number of
adiabatic pulses can be applied or the TR (and thus the measure-
ment time) should be increased. On the other hand, as the ﬁeld of
view of the endorectal coil just exceeds the volume of the prostate,
the entire ﬁeld of view of the coil can be phase encoded, so unlo-
calized adiabatic excitation can be used. An example of an adiabatic
excitation pulse is the BIR-4, of which the ﬂip angle can be adjusted
by the values of the phase shifts within the pulse [100]. Although
the ﬂip angle of the BIR-4 pulse is constant over the entire ﬁeld of
view, the excitation bandwidth decreases at larger distances from
the coil with the drop of B1þ. With the knowledge of the T1 relax-
ation times of the metabolite spins, the best combination of ﬂip
angle and TR can be selected [99].
Lateral to the prostate, muscle tissue is present. As muscle
contains large amounts of PCr, it is important to minimize
contamination from neighboring voxels. To this end, similar to 1H
MRSI, weighted k-space sampling with a Hanning ﬁlter can be
applied to decrease signal contribution from muscle tissue.
Furthermore, the spatial resolution should be as high as possible. At
this time, an effective voxel size of 3.0 cm3, after weighted sampling
and ﬁltering, was the smallest that could be obtained with sufﬁ-
cient SNR for 31P MRSI of prostate with an enrorectal coil at 7T
[101].
There are several techniques to enhance the sensitivity of 31P
spectra. For instance by 1H irradiation the effects of heteronuclear
(1H-31P) can be eliminated. With this technique the sensitivity of
certain 31P signals can be increased by merging triplets, caused by
1H-1H-31P heteronuclear coupling, into a single peak. The 1H-31P
coupling constant of the metabolites of interest is 6e7 Hz. As the
linewidth that can be obtained with shimming of the prostate at 7T
is about 15e20 Hz, the effect of merging the triplets hardly im-
proves the line width of the 31P resonances. More interesting is
exploiting the Nuclear Overhauser Effect (NOE), where water pro-
tons are saturated, which leads to signal enhancement of the 31P
signals through dipolar interactions. In the prostate, most metab-
olites showed positive NOE-enhancements, although the
enhancement was variable [99].
10. Prostate metabolites in 31P MRSI
There are compounds with 31P-atoms that reside in the prostate
at MRmeasurable concentrations. These metabolites are important
for energy and membrane phospholipid metabolism.
10.1. Phosphocreatine and adenosine triphosphate
Both PCr and ATP play an essential role in energy metabolism.
Basically, when energy is needed, ATP is hydrolyzed into ADP and
inorganic phosphate (Pi). PCr serves as an buffer by re-
phosphorylating ADP into ATP when energy demand is high.
PCr is a single resonance assigned to a chemical shift of 0 ppm.
Maps of PCr show high PCr intensities in the muscles lateral to the
prostate and low PCr levels within the prostate (Fig. 5). The T1
relaxation time at 7T for PCr is 4.1 s, which is comparable to the T1
relaxation times observed in muscle [99, 102].
ATP contains three 31P atoms (g, a and b) that resonate
around 2.5 (g), 7.5 (a) and 16.3 (b) ppm, but their exact posi-
tions are dependent on physiological conditions like pH and Mg2þ
content. The 31P-atoms are coupled with a coupling constant
around 16 Hz. To excite all ATP resonances, pulses are required to
have a large bandwidth. If the bandwidth is not sufﬁcient to fully
excite the b-ATP (and a-ATP) resonance, the g-ATP intensity is used
to estimate ATP-levels. g-ATP maps show great variation among
patients, which cannot be explained only by the coil proﬁle, and no
consistency was observed in ATP-levels in cancer tissue [101]. The
T1 relaxation time at 7T for g-ATP is 3.0 s [99]. In skeletal muscle,
the PCr/ATP ratio is between 4 and 5 [103]. This ratio is much lower
in smooth muscle tissue (104) and similar to the PCr/ATP ratio
observed in prostate: 1.3e1.5 [96,99], which indicates that most of
the PCr arises from stromal smooth muscle tissue in the prostate.
10.2. Phosphomonoesters and diesters
Next to the energy balance related metabolites, 31P MR spectra
of the prostate contain resonances of compounds participating in
phospholid metabolism. These resonances belong to the phos-
phomonoesters (PME), i.e. phosphocholine (PC) and phosphoe-
thanolamine (PE), and their glycerol derivatives, the
phosphodiesters (PDE) glycerophosphocholine (GPC) and glycer-
ophosphoethanolamine (GPE). They are involved in signalling
pathways, lipoprotein metabolism and the synthesis of phospati-
dylcholine and phosphadylethanolamine, two major cell mem-
brane compounds [104]. Themetabolites are of interest in oncology
as membrane phospholipid metabolism is altered in cancer.
PC, PE, GPC and GPE resonate around 5.6, 6.8, 2.8 and 3.2 ppm,
respectively. The 31P-atoms in these molecules are hetero-nuclear
coupled to the protons in adjacent methylene group with a
coupling constant around 6e7 Hz [105]. At lower ﬁeld strengths
without 1H decoupling, the two PMEs and two PDEs peaks are not
resolved, but with the increased spectral resolution of 7T they can
be distinguished from each other. The T1 relaxation times of these
metabolites at 7 T vary between 5.9 and 8.3 s [99].
10.3. Inorganic phosphate/tissue pH
Pi is formed during the hydrolysis of ATP in ADP. It is involved in
many metabolic processes and is essential in glycolysis and to
synthesize nucleic acids, phospholipids and proteins.
The resonance frequency Pi in cell is around 5 ppm, but the exact
frequency strongly depends on pH. As the pKa of Pi is about 6.9,
which is close to the range of physiological pH values, the chemical
shift of Pi measured relative to the PCr signal, can be employed to
determine tissue pH. In 31P spectra of the prostate, one or two
resonances in the 5.0-ppm region were observed [97e99, 101],
most likely both belonging to Pi. The observation of two Pi reso-
nances could point towards two compartments in the prostatewith
different pHs, calculated to be ~7.1 and ~7.6 [99, 101]. This hy-
pothesis of two compartments is strengthened by the observation
that both resonances have a different T1 relaxation time: 6.5 s for
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the low pH and 4.6 s for the high pH resonance [99]. Interestingly,
there was a trend towards a higher ratio of Pi (pH~7.6) over Pi
(pH~7.1) for cancerous tissue compared to normal tissue. Further
research is needed to unravel the underlying physiology of the two
resonances and their value in prostate cancer characterization.
11. Processing and interpretation of 31P MRSI
Acquisition of 31P MRSI is commonly done by a pulse-acquire
scheme, which simpliﬁes post-processing of the spectra with
respect to j-coupling evolution for coupled resonances. However,
there is a small time delay between the pulse and acquisition to
facilitate phase encoding, which requires a ﬁrst-order phase
correction. A detailed ﬁtting procedure for quantiﬁcation of the
spectra in Metabolite Report (work-in-progress package of Siemens
Healthcare) was described by Lagemaat [99]. Both Lorentzian (PCr,
PC, PE, GPC, GPE) and Gaussian (ATP and Pi) lineshapes were used
to ﬁt the metabolites and heteronuclear coupling was incorporated
for PMEs and PDEs.
There is limited information available on the interpretation of
31P MR prostate data. AT 1.5T an increase in the PME/PCr ratio was
observed in cancer compared to non-cancer tissue [95,96]. How-
ever, these results could not be reproduced at higher ﬁeld strength.
As localization was poor in that initial study, these spectra might
have suffered from signal contamination of PCr from adjacent
muscle tissue in small prostates, leading to unrepresentative ratios.
Results at 7T showed quite some overlap between the 31P metab-
olite levels in cancer and normal tissue, whichmay be due to partial
volume effects as the MR spectroscopy voxels were relatively large
(~5.1 cm3) compared to the small size of most tumors. An increased
spatial resolution is needed to fully evaluate the potential of these
metabolites as biomarker for prostate cancer. Interestingly, GPC and
GPE were nearly absent in the 7T 31P spectra of non-cancerous
tissue, but more often observed in cancerous tissue [101].
12. 13C MRSI of the prostate
The ﬁrst in vivoMR spectra of the humanprostatewere obtained
by natural abundance 13C MRS [106]. At a ﬁeld strength of 1.5 T, the
authors obtained spectra that contained, among other signals, Cit.
As the natural abundance of 13C is low (~1% of all natural carbon),
700 averages were needed to record this spectrum. With the
increasing interest in 1H MRS, which also detects Cit and does not
suffer from low natural abundance, 13C MRS of the prostate was
abandoned. Recently, 13C MRS of the prostate has regained interest
with the new technical developments in the ﬁeld of hyperpolar-
ization. The ability to increase the sensitivity of 13C-labeled sub-
strates more than 10.000 fold using dynamic nuclear
hyperpolarization (DNP) and to subsequently dissolve the sample
quickly to create a solution that can be injected, makes it possible to
study fast dynamicmetabolic processes in vivo [107]. After injection
of the hyperpolarized 13C-labeled substrate, the conversion of the
substrate into other metabolites can be observed with 13C MRS(I).
Similar to the acquisition of 31P spectra, coils dedicated to the
13C frequency are necessary to acquire 13C signals in combination
with 1H coils for anatomical reference images. For the ﬁrst in vivo
study of the human prostate, a 13C volume transmit coil was
combined with an endorectal 1H/13C receive coil [108].
The acquisition of signals from labeled 13C-substrates is chal-
lenged by T1 relaxation by which the sample starts to lose polari-
zation once dissolved and taken out of the polarizer. As polarization
also decreases due to RF excitation typically low ﬂip angle ap-
proaches are used combined with short TRs. To ensure that as much
information as possible is obtained in the short imaging window,
clever acquisition techniques are needed.
The substrates that can bemeasuredwith this technique are also
limited by their T1-relaxation time. [1e13C]-pyruvate is a popular
substrate as the quaternary carbon has a relatively long T1. It also is
a key metabolite at the crossroad of metabolic pathways (i.e.
glycolysis, citric acid cycle). The ﬁrst human in vivo study using
hyperpolarized 13C-labeled pyruvate demonstrated the safety and
feasibility of the method and also indicated clinical potential as the
ratio of lactate to pyruvate was elevated in regions of prostate
cancer (Fig. 6) [108].
The challenges of this technique include the way of polarization,
substrate administration, dedicated acquisition methods, and data
post-processing. For instance in post-processing, the effects of T1
decay and metabolic conversion and supply on signal changes has
to be taken into account, which requires complex modeling to
understand the physiology that underlie these spectral changes
[109]. A detailed review of this promising technique is beyond the
scope of this paper and more information can be found elsewhere
[110, 111].
Fig. 5. 31P MRSI of the prostate with a 31P pulse-acquire sequence. In the prostate (red voxel) the metabolites phosphoethanolamine (PE), phosphocholine (PC), inorganic phosphate
(Pi), phosphocreatine (PCr) and adenosine triphosphate (ATP) are observed. Surrounding muscle tissue is characterized by a high PCr signal.
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13. Outlook
In this paper recent developments in hardware and software
concerning prostate MRSI is reviewed. A new hardware improve-
ment involves the development of a dual channel endorectal
receive coil with higher SNR in the dorsal part of the prostate
compared to single channel receive coils. Both inﬂatable and rigid
coil designs have been equipped with this technology. Whether
further improvements can bemade by addingmore coil elements is
questionable, as the penetration depth decreases for smaller coil
elements. However, further optimization of the external phased
array coils towards MR without endorectal coil is probably more of
clinical interest as it results in shorter patient preparation times,
improved patient comfort and MRSI options for individual metab-
olite maps with uniform B1 over the prostate.
Another hardware advance is the increased availability of 7T
systems. There is no information available yet whether the
increased SNR and spectral resolution of this ﬁeld strength will
have added value for prostate cancer management. However, it can
be expected that the increased SNR can be used for either higher
spatial resolution or shorter measurement times. As discussed,
these measurements are not straightforward yet; there is a lot of
room for improvement and clever acquisition techniques with
minimal SAR-deposition are required. Ultra-high ﬁeld MR systems
Fig. 6. Images were obtained from a patient with serum PSA of 9.5 ng/ml, who was diagnosed with bilateral biopsy-proven Gleason grade 3 þ 3 prostate cancer and received
hyperpolarized [1e13C] pyruvate (0.43 ml/kg). The axial T2-weighted image shows a unilateral region of reduced signal intensity (red arrows), which is consistent with a reduction
in the corresponding apparent diffusion coefﬁcient (ADC). The 1H spectral arrays supported these ﬁndings, with voxels with reduced citrate and elevated choline/citrate (highlighted
in pink) on the right side of the gland and voxels with normal metabolite ratios on the left side. The 13C spectral arrays show voxels with elevated levels of hyperpolarized [1e13C]
lactate/[1e13C]pyruvate (highlighted in pink) on both the right and left sides of the prostate. The location of colored regions in the metabolite image overlay had a ratio of [1e13C]
lactate/[1e13C]pyruvate greater than or equal to 0.6. Reprinted with permission from [107].
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open the possibility to perform 3D 31PMRSI of the entire prostate in
a reasonable measurement time. There are some indications that
31P MR spectra might contain interesting information for prostate
cancer management, but more patients need to be evaluated,
preferably with more aggressive and larger tumors.
Besides progress in hardware, the recent improvements in 1H
MRSI acquisition are of interest, in particular for clinical applica-
tions. The sLASER sequence enables accurate volume selection of
the prostate and has aminimal chemical shift displacement artefact
resulting in a more robust acquisition with little lipid signal
contamination. The sLASER sequence combined with a spiral
readout, offers a ﬂexible approach to acquire 3D 1HMRSI data of the
prostate in 5e8 min without an endorectal coil at 3T. This mea-
surement time approaches the acquisition time of techniques like
DWI and DCE-MRI. Still, for a more widespread use of MRSI in a
mpMRI examination, not only fast and robust acquisition is desired,
but also display of the results in a reliable and easy digestible way.
To this end, full automation in post-processing is needed. Further
reﬁnement of MRSI acquisition is possible, such as movement
correction.
With fully automated post-processing and intuitive display in
place, MRSI might be a good alternative for DCE-MRI in an mpMRI
prostate exam. The use of gadolinium as contrast agent is under
discussion, because of complications such as accumulation of re-
sidual gadolinium in the brain and bone, and nephrogenic systemic
ﬁbrosis [111e113]. Especially for clinical applications where MR-
examinations are repeated over time, MRSI might be preferable
over DCE-MRI. Several studies have shown the ability of prostate
MRSI (in particular combined with DWI) to identify aggressive
prostate cancers, suggesting an important role for MRSI in selecting
patients for active surveillance programs [114, 115].
Lastly, the promising development in hyperpolarized 13C MRSI
are discussed. So far, only [1e13C]-pyruvate has been studied in the
human prostate, but more substrates can be polarized to investi-
gate metabolic processes. In contrast to 1H and 31P MRSI providing
static levels of metabolites, hyperpolarized 13C MRSI monitors dy-
namic processes of metabolism. The true value of [1e13C]-pyruvate
and other substrates in cancer diagnosis needs more investigation.
A prostate MR examination is multi-parametric and at this
moment, MRSI is often not included in this approach. However,
with all recent advancements, a new evaluation of the comple-
mentary role of MRSI for prostate cancer management is in place.
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